By Steve Usdin
Contributing Editor

BETHESDA, Md. - The FDA's Oncologic Drugs Advisory Committee (ODAC) on Friday unanimously recommended approval of NaPro BioTherapeutics Inc.'s Paxene for treatment of AIDS-related Kaposi's sarcoma in patients following failure of first-line or subsequent systemic chemotherapy. But although the unanimous recommendation might normally presage a swift approval, final approval of Paxene will hinge on legal and regulatory issues that were not addressed by ODAC.